Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Keywords/Phrases:  PD 0332991
Results 1-25 of 461 for your search:
Start Over
PD-0332991 in Treating Patients with Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11-003234, NCI-2012-00287, NCT01536743
PD-0332991, Fluorouracil, and Oxaliplatin in Treating Patients With Refractory Metastatic Colorectal Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2011-219, NCI-2013-00658, NCT01522989
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201301106, NCI-2012-02202, NCT01723774
PD-0332991 and Paclitaxel in Treating Patients With Metastatic Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 02111, NCI-2011-00414, NCT01320592
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70, Postmenopausal
Trial IDs: A5481027, NCI-2015-01375, NCT02297438
Palbociclib Isethionate in Treating Younger Patients with Recurrent, Progressive, or Refractory Central Nervous System Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: PBTC-042, NCI-2014-00640, NCT02255461
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: 18 and over
Trial IDs: GBG78/BIG 1-13/NSABP-B-54-I, NCI-2014-02553, 2013-001040-62, NCT01864746
Palbociclib in Treating Patients with Metastatic Urothelial Cancer after First-Line Chemotherapy Failure
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 1406, NCI-2015-00532, 14-2196, WI187190, NCT02334527
Palbociclib and Cetuximab in Treating Patients with Squamous Cell Carcinoma of the Head and Neck
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201404139, NCI-2014-01079, 14-X031, NCT02101034
Ibrutinib and Palbociclib Isethionate in Treating Patients with Previously Treated Mantle Cell Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 1403014853, NCI-2014-01202, 9534, NCT02159755
Palbociclib Isethionate and Ado-Trastuzumab Emtansine in Treating Patients with Recurrent or Metastatic HER2-Positive Breast Cancer
Phase: Phase I
Type: Treatment
Age: 18 to 90
Trial IDs: SCCC-05113, NCI-2014-00821, 042013-042, 8843, Mod13_STU 042013-042, Mod9_STU 042013-042, NCT01976169
Palbociclib and PD0325901 in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-506, NCI-2014-00940, NCT02022982
Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A5481059, NCI-2015-01693, 2015-001307-31, NCT02501902
Palbociclib and Endocrine Therapy in Treating Patients with Hormone Receptor-Positive Stage II-III Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-559, NCI-2014-00937, WI180528, NCT02040857
Palbociclib and Bazedoxifene in Treating Patients with Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 15-060, NCI-2015-01604, WI196579, NCT02448771
Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: A5481044, NCI-2015-01296, 2015-000515-41, NCT02499120
Palbociclib and Bicalutamide in Treating Patients with Metastatic Androgen Receptor Positive or Triple Negative Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-207, NCI-2015-02043, NCT02605486
Androgen Deprivation Therapy with or without Palbociclib Isethionate in Treating Patients with RB-Positive Metastatic Hormone-Sensitive Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2013.117, NCI-2014-01922, HUM00082715, NCT02059213
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1400, NCI-2014-00627, S1400A, S1400B, S1400C, S1400D, S1400E, S1400I, NCT02154490
Palbociclib in Combination with Fulvestrant or Tamoxifen Citrate in Treating Patients with Locally Advanced or Metastatic Hormone Receptor Positive Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 147522, NCI-2015-01791, CC#147522, TBCRC035, NCT02384239
Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: R2810-ONC-1425, NCI-2015-01855, NCT02520245
Anti-PD-L1 Monoclonal Antibody MPDL3280A and Stereotactic Ablative Radiotherapy in Treating Patients with Stage IV Non-small Cell Lung Cancer
Phase: Phase I
Type: Treatment
Age: 19 and over
Trial IDs: UCDCC#251, NCI-2014-02629, 685389, 685389-2, ML29551, NCT02400814
A Phase III Study of Atezolizumab Treatment Versus Observation as Adjuvant Therapy in Patients With PD-L1 Positive, High Risk Muscle Invasive Bladder Cancer After Cystectomy [IMvigor010]
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: WO29636, NCI-2015-01334, 2014-005603-25, NCT02450331
Start Over